异烟肼耐药结核的一线药物治疗:系统综述与荟萃分析
该系统综述与荟萃分析更新了既往研究,纳入2015年3月31日前发表的随机试验和队列研究,分析细菌学确诊的异烟肼耐药(非耐多药)结核患者接受标准化一线药物治疗的失败和复发结局。
要点
- 异烟肼耐药结核使用一线药物失败或复发合并率为15%(95%CI 12-18)。
- WHO新患者标准方案治疗异烟肼耐药结核:失败11%、复发10%、获得耐多药8%。
核心结论
- 异烟肼耐药结核使用一线药物治疗结局欠佳,支持需要更好的治疗方案。
- 对新病例进行标准化经验性治疗可能显著促进耐多药流行,尤其在异烟肼耐药高流行地区。
研究设计与样本
- 系统综述与荟萃分析,更新既往综述,纳入截至2015年3月31日发表的英文、法文或西班牙文随机试验和队列研究。
- 纳入标准:细菌学确诊的异烟肼耐药(非耐多药,即不耐利福平)结核患者,接受标准化治疗,且失败和复发经细菌学确诊。
- 采用随机效应荟萃分析合并治疗结局。
主要发现
- 异烟肼耐药结核患者失败或复发(或两者)合并率为15%(95%CI 12-18),药物敏感结核患者为4%(95%CI 3-5)。
- 在初始异烟肼耐药且获得性耐药的患者中,96%(95%CI 93-99)获得耐多药结核。
- WHO新患者标准方案治疗异烟肼耐药结核:治疗失败11%(95%CI 6-17)、复发10%(95%CI 5-15)、获得耐多药8%(95%CI 3-13)。
- WHO既往治疗患者标准方案治疗异烟肼耐药结核:治疗失败6%(95%CI 2-10)、复发5%(95%CI 2-8)、获得耐多药3%(95%CI 0-6)。
关键数值与推荐
- 异烟肼耐药结核使用所有药物方案的失败或复发合并率为15%(95%CI 12-18)。
- WHO新患者标准方案治疗异烟肼耐药结核的失败率11%(95%CI 6-17)、复发率10%(95%CI 5-15)、获得耐多药率8%(95%CI 3-13)。
- WHO既往治疗患者标准方案治疗异烟肼耐药结核的失败率6%(95%CI 2-10)、复发率5%(95%CI 2-8)、获得耐多药率3%(95%CI 0-6)。
临床怎么用
- 临床应认识到异烟肼耐药结核使用一线标准方案失败和复发风险较高,需加强治疗监测。
- 在异烟肼耐药高流行地区,新病例的标准化经验性治疗可能促进耐多药结核流行,需考虑优化方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The results of some reports have suggested that treatment of isoniazid-resistant tuberculosis with the recommended regimens of first-line drugs might be suboptimal. We updated a previous systematic review of treatment outcomes associated with use of first-line drugs in patients with tuberculosis resistant to isoniazid but not rifampicin. METHODS: In this systematic review, we updated the results of a previous review to include randomised trials and cohort studies published in English, French, or Spanish to March 31, 2015, containing results of standardised treatment of patients with bacteriologically confirmed isoniazid-resistant tuberculosis (but not multidrug-resistant tuberculosis-ie, not resistant to rifampicin) in whom failure and relapse were bacteriologically confirmed. Results in patients with drug-sensitive tuberculosis included in the same studies were also analysed. We pooled treatment outcomes with random-effects meta-analysis. FINDINGS: We identified 19 cohort studies and 33 trials with 3744 patients with isoniazid-resistant tuberculosis and 19 012 patients with drug-sensitive disease. The pooled rates of failure or relapse, or both, and acquired drug resistance with all drug regimens were 15% (95% CI 12-18) and 3·6% (2-5), respectively, in patients with isoniazid-resistant tuberculosis and 4% (3-5) and 0·6% (0·3-0·9) in those with drug-sensitive tuberculosis. Of patients with initial isoniazid-resistant tuberculosis with acquired drug resistance, 96% (93-99) had acquired multidrug-resistant disease. Treatment of isoniazid-resistant tuberculosis with the WHO standard regimen for new patients resulted in treatment failure, relapse, and acquired multidrug resistance in 11% (6-17), 10% (5-15) and 8% (3-13), respectively; treatment with the standard WHO regimen for previously treated patients resulted in treatment failure in 6% (2-10), relapse in 5% (2-8), and acquisition of multidrug resistance in 3% (0-6). For patients with drug-sensitive disease treated with the standard retreatment regimen the rates were 1% (0-2), 5% (4-7), and 0·3% (0-0·6). INTERPRETATION: Treatment of isoniazid-resistant tuberculosis with first-line drugs resulted in suboptimal outcomes, supporting the need for better regimens. Standardised empirical treatment of new cases could be contributing substantially to the multidrug-resistant epidemic, particularly in settings where the prevalence of isoniazid resistance is high. FUNDING: Canadian Institutes of Health Research.
引用
- Gegia M, Winters N, Benedetti A, et al. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2016. PMID: 27865891. doi:10.1016/S1473-3099(16)30407-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。